Document is current

Article History

Received: 9 December 2024

Accepted: 10 December 2024

First Online: 25 December 2024

Disclosure

: Yuko Kitagawa reports grants and personal fees from Asahi Kasei Pharma Corporation, Otsuka Pharmaceutical Factory, Inc., Nippon Covidien Inc., Kaken Pharmaceutical Co., Ltd, and EA Pharma Co., Ltd; grants, personal fees, and others from Ono Pharmaceutical Co., Ltd, Taiho Pharmaceutical Co., Ltd, and Chugai Pharmaceutical Co., Ltd; personal fees from AstraZeneca K.K., Ethicon Inc., Olympus Corporation, Shionogi & Co., Ltd, Bristol-Myers Squibb K.K., MSD K.K., Smith & Nephew K.K., Aska Pharmaceutical Co., Ltd, Miyarisan Pharmaceutical Co., Ltd, Toray Industries, Inc., Daiichi Sankyo Company, Ltd, Chugai Foundation for Innovative Drug Discovery Science, and Nippon Kayaku Co., Ltd; grants from Yakult Honsha Co., Ltd, Tsumura & Co., Sumitomo Pharma Co., Ltd, Eisai Co., Ltd, Kyowa Kirin Co., Ltd, Medicon Inc., Takeda Pharmaceutical Co., Ltd, and Teijin Pharma Ltd; and personal fees from Intuitive Surgical G.K., outside the submitted work. Yuko Kitagawa has equity for Direava Inc. Masashi Takeuchi is Chief Executive Officer for Direava Inc. Tasuku Furube, Satoru Matsuda, and Hirofumi Kawakubo have no conflicts of interest to declare that may be relevant to the contents of this study.